{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T11:07:44Z","timestamp":1793444864074,"version":"4.5.0"},"reference-count":107,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.phrs.2021.106037","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T17:53:53Z","timestamp":1639590833000},"page":"106037","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":184,"special_numbering":"C","title":["Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update"],"prefix":"10.1016","volume":"175","author":[{"given":"Robert","family":"Roskoski Jr.","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2021.106037_bib1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nrd773","article-title":"Protein kinases \u2013 the major drug targets of the twenty-first century?","volume":"1","author":"Cohen","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2021.106037_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2015.07.010","article-title":"A historical overview of protein kinases and their targeted small molecule inhibitors","volume":"100","author":"Roskoski","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2021.106037_bib3","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: progress and future directions","volume":"20","author":"Cohen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2021.106037_bib4","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","article-title":"Trends in kinase drug discovery: targets, indications and inhibitor design","volume":"20","author":"Attwood","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2021.106037_bib5","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.tips.2019.09.002","article-title":"The landscape of atypical and eukaryotic protein kinases","volume":"40","author":"Kanev","year":"2019","journal-title":"Trends Pharm. Sci."},{"key":"10.1016\/j.phrs.2021.106037_bib6","first-page":"23","article-title":"PKIDB: a curated, annotated and updated database of protein kinase inhibitors in clinical trials","author":"Carles","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.phrs.2021.106037_bib7","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/med.21409","article-title":"Approved and experimental small-molecule oncology kinase inhibitor drugs: a mid-2016 overview","volume":"37","author":"Fischer","year":"2017","journal-title":"Med Res. Rev."},{"key":"10.1016\/j.phrs.2021.106037_bib8","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.phrs.2021.106037_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105579","article-title":"Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies","volume":"168","author":"Roskoski","year":"2021","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2021.106037_bib10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.phrs.2019.03.006","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors","volume":"144","author":"Roskoski","year":"2019","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2021.106037_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104609","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update","volume":"152","author":"Roskoski","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2021.106037_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105463","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2021 update","volume":"165","author":"Roskoski","year":"2021","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2021.106037_bib13","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1021\/acs.jmedchem.5b01273","article-title":"AXL inhibitors in cancer: a medicinal chemistry perspective","volume":"59","author":"Myers","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2021.106037_bib14","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd1346","article-title":"Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia","volume":"3","author":"Roth","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2021.106037_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105422","article-title":"Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs)","volume":"165","author":"Roskoski","year":"2021","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2021.106037_bib16","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.1862342","article-title":"Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase","volume":"253","author":"Knighton","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.phrs.2021.106037_bib17","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.tibs.2015.09.002","article-title":"Dynamics-driven allostery in protein kinases","volume":"40","author":"Kornev","year":"2015","journal-title":"Trends Biochem Sci."},{"key":"10.1016\/j.phrs.2021.106037_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100746","article-title":"From structure to the dynamic regulation of a molecular switch: a journey over 3 decades","volume":"296","author":"Taylor","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2021.106037_bib19","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.phrs.2018.11.035","article-title":"Cyclin-dependent protein serine\/threonine kinase inhibitors as anticancer drugs","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2021.106037_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105660","article-title":"Hydrophobic and polar interactions of FDA-approved small molecule protein kinase inhibitors with their target enzymes","volume":"169","author":"Roskoski","year":"2021","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2021.106037_bib21","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1096\/fasebj.9.8.7768349","article-title":"Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification","volume":"9","author":"Hanks","year":"1995","journal-title":"FASEB J."},{"key":"10.1016\/j.phrs.2021.106037_bib22","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/pro.5560030203","article-title":"cAMP-dependent protein kinase: crystallographic insights into substrate recognition and phosphotransfer","volume":"3","author":"Madhusudan, Trafny","year":"1994","journal-title":"Protein Sci."},{"key":"10.1016\/j.phrs.2021.106037_bib23","doi-asserted-by":"crossref","first-page":"15733","DOI":"10.1021\/bi971438n","article-title":"Participation of ADP dissociation in the rate-determining step in cAMP-dependent protein kinase","volume":"36","author":"Zhou","year":"1997","journal-title":"Biochemistry"},{"key":"10.1016\/j.phrs.2021.106037_bib24","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.bioorg.2011.07.004","article-title":"Protein kinase biochemistry and drug discovery","volume":"39","author":"Schwartz","year":"2011","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.phrs.2021.106037_bib25","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.bbapap.2009.10.017","article-title":"Defining the conserved internal architecture of a protein kinase","volume":"1804","author":"Kornev","year":"2010","journal-title":"Biochim Biophys. Acta"},{"key":"10.1016\/j.phrs.2021.106037_bib26","doi-asserted-by":"crossref","first-page":"6818","DOI":"10.1073\/pnas.1814279116","article-title":"Defining a new nomenclature for the structures of active and inactive kinases","volume":"116","author":"Modi","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2021.106037_bib27","first-page":"gkab920","article-title":"Kincore: a web resource for structural classification of protein kinases and their inhibitors","author":"Modi","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2021.106037_bib28","doi-asserted-by":"crossref","first-page":"17783","DOI":"10.1073\/pnas.0607656103","article-title":"Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism","volume":"103","author":"Kornev","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2021.106037_bib29","doi-asserted-by":"crossref","first-page":"14377","DOI":"10.1073\/pnas.0807988105","article-title":"A helix scaffold for the assembly of active protein kinases","volume":"105","author":"Kornev","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2021.106037_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001680","article-title":"Deciphering the structural basis of eukaryotic protein kinase regulation","volume":"11","author":"Meharena","year":"2013","journal-title":"PLoS Biol."},{"key":"10.1016\/j.phrs.2021.106037_bib31","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2021.106037_bib32","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"The ErbB\/HER family of protein-tyrosine kinases and cancer","volume":"79","author":"Roskoski","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2021.106037_bib33","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.phrs.2014.06.001","article-title":"ErbB\/HER protein-tyrosine kinases: Structure and small molecule inhibitors","volume":"87","author":"Roskoski","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2021.106037_bib34","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.phrs.2018.11.014","article-title":"Small molecule inhibitors targeting the EGFR\/ErbB family of protein-tyrosine kinases in human cancers","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2021.106037_bib35","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.phrs.2012.11.007","article-title":"Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition","volume":"68","author":"Roskoski","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2021.106037_bib36","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.phrs.2017.01.007","article-title":"Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers","volume":"117","author":"Roskoski","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2021.106037_bib37","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1517\/17460441.2013.813015","article-title":"The preclinical profile of crizotinib in the treatment of non-small cell lung cancer and other neoplastic disorders","volume":"8","author":"Roskoski","year":"2013","journal-title":"Expert Opin. Drug Dis."},{"key":"10.1016\/j.phrs.2021.106037_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104567","article-title":"The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder","volume":"151","author":"Roskoski","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2021.106037_bib39","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.phrs.2018.01.021","article-title":"The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders","volume":"129","author":"Roskoski","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2021.106037_bib40","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.phrs.2018.04.020","article-title":"The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders","volume":"133","author":"Roskoski","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2021.106037_bib41","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.phrs.2017.03.010","article-title":"Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas","volume":"120","author":"Roskoski","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2021.106037_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2017.12.021","article-title":"Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers","volume":"128","author":"Roskoski","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2021.106037_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104725","article-title":"The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias","volume":"155","author":"Roskoski","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2021.106037_bib44","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.phrs.2017.04.022","article-title":"ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers","volume":"121","author":"Roskoski","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2021.106037_bib45","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.phrs.2015.01.003","article-title":"Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors","volume":"94","author":"Roskoski","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2021.106037_bib46","series-title":"Reference Module in Life Sciences","first-page":"1","article-title":"Src family tyrosine kinases","author":"Frame","year":"2017"},{"key":"10.1016\/j.phrs.2021.106037_bib47","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.phrs.2016.09.011","article-title":"Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms","volume":"113","author":"Roskoski","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2021.106037_bib48","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","article-title":"Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2021.106037_bib49","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.bbrc.2011.11.145","article-title":"MEK1\/2 dual-specificity protein kinases: structure and regulation","volume":"417","author":"Roskoski","year":"2012","journal-title":"Biochem Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2021.106037_bib50","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.phrs.2016.12.009","article-title":"Allosteric MEK1\/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas","volume":"117","author":"Roskoski","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2021.106037_bib51","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.phrs.2018.08.013","article-title":"Targeting oncogenic Raf protein-serine\/threonine kinases in human cancers","volume":"135","author":"Roskoski","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2021.106037_bib52","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.bbrc.2010.07.092","article-title":"RAF protein-serine\/threonine kinases: structure and regulation","volume":"399","author":"Roskoski","year":"2010","journal-title":"Biochem Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2021.106037_bib53","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.phrs.2012.04.005","article-title":"ERK1\/2 MAP kinases: structure, function, and regulation","volume":"66","author":"Roskoski","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2021.106037_bib54","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.phrs.2019.01.039","article-title":"Targeting ERK1\/2 protein-serine\/threonine kinases in human cancers","volume":"142","author":"Roskoski","year":"2019","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2021.106037_bib55","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.phrs.2016.03.012","article-title":"Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs","volume":"107","author":"Roskoski","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2021.106037_bib56","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0968-0896(98)00099-6","article-title":"A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src","volume":"6","author":"Liu","year":"1998","journal-title":"Bioorg. Med Chem."},{"key":"10.1016\/j.phrs.2021.106037_bib57","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1146\/annurev-biochem-090308-173656","article-title":"The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling","volume":"80","author":"Dar","year":"2011","journal-title":"Annu Rev. Biochem."},{"key":"10.1016\/j.phrs.2021.106037_bib58","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.chembiol.2018.05.002","article-title":"Redefining the protein kinase conformational space with machine learning","volume":"25","author":"Ung","year":"2018","journal-title":"Cell Chem. Biol."},{"issue":"D1","key":"10.1016\/j.phrs.2021.106037_bib59","doi-asserted-by":"crossref","first-page":"D552","DOI":"10.1093\/nar\/gkaa945","article-title":"KinaseMD: kinase mutations and drug response database","volume":"49","author":"Hu","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2021.106037_bib60","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1021\/jm901443h","article-title":"Through the \u201cgatekeeper door\u201d: exploiting the active kinase conformation","volume":"53","author":"Zuccotto","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2021.106037_bib61","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1039\/C2MD20180A","article-title":"Approaches to discover non-ATP site inhibitors","volume":"4","author":"Gavrin","year":"2013","journal-title":"Med Chem. Commun."},{"key":"10.1016\/j.phrs.2021.106037_bib62","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.2174\/138161212800672813","article-title":"New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors","volume":"18","author":"Lamba","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2021.106037_bib63","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1021\/jm0608107","article-title":"Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors","volume":"50","author":"Liao","year":"2007","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2021.106037_bib64","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1021\/jm400378w","article-title":"KLIFS: a knowledge-based structural database to navigate kinase-ligand interaction space","volume":"57","author":"van Linden","year":"2014","journal-title":"J. Med. Chem."},{"issue":"D1","key":"10.1016\/j.phrs.2021.106037_bib65","doi-asserted-by":"crossref","first-page":"D365","DOI":"10.1093\/nar\/gkv1082","article-title":"KLIFS: a structural kinase-ligand interaction database","volume":"44","author":"Kooistra","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2021.106037_bib66","first-page":"gkaa895","article-title":"KLIFS: an overhaul after the first 5 years of supporting kinase research","author":"Kanev","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2021.106037_bib67","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1021\/acschembio.9b00476","article-title":"Surprising non-additivity of methyl groups in drug-kinase interaction","volume":"14","author":"Wienen-Schmidt","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.phrs.2021.106037_bib68","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.2174\/1568026617666170224121313","article-title":"Structure-based virtual screening approaches in kinase-directed drug discovery","volume":"17","author":"Bajusz","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.phrs.2021.106037_bib69","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.tips.2015.04.005","article-title":"FDA-approved small-molecule kinase inhibitors","volume":"36","author":"Wu","year":"2015","journal-title":"Trends Pharm. Sci."},{"key":"10.1016\/j.phrs.2021.106037_bib70","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1021\/jm2006222","article-title":"Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase","volume":"54","author":"Guagnano","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2021.106037_bib71","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.2147\/OTT.S272208","article-title":"Targeted therapy for advanced or metastatic cholangiocarcinoma: focus on the clinical potential of infigratinib","volume":"14","author":"Yu","year":"2021","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.phrs.2021.106037_bib72","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations","volume":"383","author":"Paik","year":"2020","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.phrs.2021.106037_bib73","article-title":"FDA approval summary: capmatinib and tepotinib for the treatment of metastatic NSCLC harboring MET exon 14 skipping mutations or alterations","author":"Mathieu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2021.106037_bib74","doi-asserted-by":"crossref","first-page":"9134","DOI":"10.1158\/0008-5472.CAN-05-4290","article-title":"KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties","volume":"66","author":"Nakamura","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2021.106037_bib75","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-74028-3","article-title":"FDA approval summary: tivozanib for relapsed or refractory renal cell carcinoma","author":"Chang","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2021.106037_bib76","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/s40265-021-01593-z","article-title":"Belumosudil: first approval","volume":"81","author":"Blair","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2021.106037_bib77","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2021012021","article-title":"Belumosudil for chronic graft-versus-host disease (cGVHD) after 2 or more prior lines of therapy: the ROCKstar study","author":"Cutler","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2021.106037_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108823","article-title":"ROCK2, a critical regulator of immune modulation and fibrosis has emerged as a therapeutic target in chronic graft-versus-host disease","volume":"230","author":"Zanin-Zhorov","year":"2021","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.phrs.2021.106037_bib79","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.20.02754","article-title":"ROCK2 inhibition with belumosudil (KD025) for the treatment of chronic graft-versus-host disease","volume":"39","author":"Jagasia","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2021.106037_bib80","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1158\/2159-8290.CD-20-1683","article-title":"Mobocertinib (TAK-788): a targeted inhibitor of EGFR exon 20 insertion mutants in non-small cell lung cancer","volume":"11","author":"Gonzalvez","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.phrs.2021.106037_bib81","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1158\/2159-8290.CD-20-1598","article-title":"Activity and safety of mobocertinib (TAK-788) in previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations from a phase I\/II trial","volume":"11","author":"Riely","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.phrs.2021.106037_bib82","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1093\/annonc\/mdz278","article-title":"G1T28-02 Study Group. Myelopreservation with the CDK4\/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib\/randomized phase II trial","volume":"30","author":"Weiss","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phrs.2021.106037_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101206","article-title":"Concerning FDA approval of trilaciclib (Cosela) in extensive-stage small-cell lung cancer","volume":"14","author":"Powell","year":"2021","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.phrs.2021.106037_bib84","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.phrs.2021.106037_bib85","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S1359-6446(04)03069-7","article-title":"Ligand efficiency: a useful metric for lead selection","volume":"9","author":"Hopkins","year":"2004","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.phrs.2021.106037_bib86","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/nrd2445","article-title":"The influence of drug-like concepts on decision-making in medicinal chemistry","volume":"6","author":"Leeson","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2021.106037_bib87","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s11095-015-1779-y","article-title":"Thermodynamic proxies to compensate for biases in drug discovery methods","volume":"33","author":"Ekins","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2021.106037_bib88","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nrd4163","article-title":"The role of ligand efficiency metrics in drug discovery","volume":"13","author":"Hopkins","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2021.106037_bib89","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.addr.2016.01.018","article-title":"Molecular inflation, attrition, and the rule of five","volume":"101","author":"Leeson","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.phrs.2021.106037_bib90","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2021.106037_bib91","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1023\/A:1008130001697","article-title":"Property distribution of drug-related chemical databases","volume":"14","author":"Oprea","year":"2000","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.phrs.2021.106037_bib92","doi-asserted-by":"crossref","first-page":"7210","DOI":"10.1021\/acs.jmedchem.1c00416","article-title":"Target-based evaluation of \u201cdrug-like\u201d properties and ligand efficiencies","volume":"64","author":"Leeson","year":"2021","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2021.106037_bib93","doi-asserted-by":"crossref","first-page":"8091","DOI":"10.1021\/jm300967g","volume":"55","author":"Cui","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2021.106037_bib94","first-page":"3559","article-title":"The first general index of molecular complexity","volume":"1103","author":"Bertz","year":"1981","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.phrs.2021.106037_bib95","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1021\/ci00054a004","article-title":"Molecular complexity: a simplified formula adapted to individual atoms","volume":"27","author":"Hendrickson","year":"1987","journal-title":"J. Chem. Inf. Comput Sci."},{"key":"10.1016\/j.phrs.2021.106037_bib96","doi-asserted-by":"crossref","first-page":"7206","DOI":"10.1021\/jm500515d","article-title":"Physicochemical descriptors of aromatic character and their use in drug discovery","volume":"57","author":"Ritchie","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2021.106037_bib97","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.drudis.2016.07.007","article-title":"Quality guidelines for oral drug candidates: dose, solubility and lipophilicity","volume":"21","author":"Bayliss","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.phrs.2021.106037_bib98","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nrd.2018.52","article-title":"Unexplored therapeutic opportunities in the human genome","volume":"17","author":"Oprea","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2021.106037_bib99","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13045-020-00977-0","article-title":"Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020)","volume":"13","author":"Huang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.phrs.2021.106037_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104392","article-title":"The new entries in the therapeutic armamentarium: the small molecule JAK inhibitors","volume":"147","author":"Bechman","year":"2019","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2021.106037_bib101","first-page":"219","article-title":"Small-molecule protein kinase inhibitors and the risk of fungal infections","author":"Bechman","year":"2019","journal-title":"Curr. Fungal Infect. Rep."},{"key":"10.1016\/j.phrs.2021.106037_bib102","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3390\/ijms22020566","article-title":"The kinase chemogenomic set (KCGS): an open science resource for kinase vulnerability identification","volume":"22","author":"Wells","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2021.106037_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105412","article-title":"Posttranslational modifications as therapeutic targets for intestinal disorders","author":"Choo","year":"2021","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2021.106037_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105806","article-title":"Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS","volume":"172","author":"Roskoski","year":"2021","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2021.106037_bib105","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1038\/s41467-021-23165-1","article-title":"Crowdsourced mapping of unexplored target space of kinase inhibitors","volume":"12","author":"Cicho\u0144ska","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2021.106037_bib106","doi-asserted-by":"crossref","first-page":"13764","DOI":"10.1002\/anie.201914525","article-title":"New promise and opportunities for allosteric kinase inhibitors","volume":"59","author":"Lu","year":"2020","journal-title":"Angew. Chem. Int Ed. Engl."},{"key":"10.1016\/j.phrs.2021.106037_bib107","doi-asserted-by":"crossref","unstructured":"Roskoski R. Jr. Guidelines for preparing color figures for everyone including the colorblind. Pharmacol Res. 2017;119:240\u20131. doi: 10.1016\/j.phrs.2017.02.005. Erratum in: Pharmacol Res. 2019;139:569. doi: \u300810.1016\/j.phrs.2018.09.019\u3009.","DOI":"10.1016\/j.phrs.2018.09.019"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821006216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821006216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:35:24Z","timestamp":1760913324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661821006216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":107,"alternative-id":["S1043661821006216"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2021.106037","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2021.106037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106037"}}